2016;34(suppl; abstr 9027). 117. Antonia S,et al, Safet y and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study The Lancet Oncology , Volume 17, I ssue 3, March 2016, Pages 299 –308. 118. Tanvet yanon T, Gray JE, Antonia SJ. PD -1 checkpoint blockade alone or combined PD-1 and CTLA -4 blockade as immunotherap y for lung cancer? Expert Opin Biol Ther.